On June 21st, PwC’s Health Research Institute (HRI) released its annual Medical Cost Trend: Behind the Numbers 2017 report. PwC’s HRI anticipates a 6.5% growth rate for 2017—the same as was projected for 2016. The report identifies the key inflators and deflators as well as historical context to better understand the medical cost trend for 2017. Increases in the trend due to utilization of convenient care access points and an uptick in behavioral healthcare benefits for employees are being offset by more aggressive strategies by pharmacy benefit

1. Source: PwC Health Research Institute analysis based on CMS National Health Expenditure Private Health Data
Recent trends in health insurance costs are at historical lows
© 2016 PwC. All rights reserved. PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity. Please seewww.pwc.com/structure
for further details. 172489-2016
0%
5%
10%
15%
20%
25%
201520102005200019951990198519801975197019651961
Annualgrowthinprivate
healthinsurancespending
Annual trend
Linear trend
Four-year moving
average
Source: PwC Health Research Institute analysis based on CMS National Health Expenditures Private Health Insurance Component data

2. © 2016 PwC. All rights reserved. PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity. Please seewww.pwc.com/structure
for further details. 172489-2016
-4%
0%
4%
8%
12%
201520142013201220112010200920082007200620052004200320022001
Source: PwC Health Research Institute analysis of Bureau of Labor Statistics data
Price, not utilization, is the historical force behind
medical cost trend
OVERALL HEALTHCARE COST:
Employer Health Benefit Costs
PRICE:
PwC Benefit Price Index
UTILIZATION:
PwC Utilization Index
Annualgrowth

3. © 2016 PwC. All rights reserved. PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity. Please seewww.pwc.com/structure
for further details. 172489-2016
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
OtherPharmacyOutpatientInpatientPhysician
Source: Milliman Medical Index for 2007 and PwC Health Research Institute projections of 2017 medical spending based on the
2016 Milliman Medical Index. http://us.milliman.com/insight/?pfld=2413
Roughly half of employer health costs stem from hospital
inpatient and outpatient services; the prescription drug
share is small but increasing
Shareofemployerhealthbenefits
30%
16%
19%
14%
17%
4% 4%
2007 Share (Milliman) 2017 Share (PwC Projection) % Change since 2007
36%
30%30%
-17%
0%
19%
21%
0%
Medical index—components of spending

4. © 2016 PwC. All rights reserved. PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity. Please seewww.pwc.com/structure
for further details. 172489-2016
Source: PwC Health Research Institute medical cost trends 2007–2017
HRI’s projected medical cost trend 2007–2017HRI’sprojectedmedicalcosttrend
20172016201520142013201220112010200920082007
6.5%
6.5%6.8%6.5%
7.5%
8.5%
9%9%9.2%
9.9%
11.9%

5. © 2016 PwC. All rights reserved. PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity. Please seewww.pwc.com/structure
for further details. 172489-2016
Use of retail clinics is increasing along with the number of
places for treatment
Source: PwC Health Research Institute Consumer Survey and Convenient Care Association data
0
500
1,000
1,500
2,000
2,500
3,000
3,500
Numberofretailclinics
Percentofconsumerswhouseretailclinics
10%
30%
50%
70%
80%
201620152014201320122011
20%
40%
60%
0%
24%
36%
40%
Projected

6. © 2016 PwC. All rights reserved. PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity. Please seewww.pwc.com/structure
for further details. 172489-2016
The share of employer health spending on mental health
services is increasing
Source: PwC Health Research Institute analysis based on Medical Expenditure Panel Survey data
4.0%
4.5%
5.0%
5.5%
6.0%
6.5%
201320122011201020092008200720062005
Annual Increase
Linear Trend
Mentalhealthspendingasa
shareoftotalemployerhealthspending

7. © 2016 PwC. All rights reserved. PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity. Please seewww.pwc.com/structure
for further details. 172489-2016
The new focus on mental health parity will likely increase
utilization in 2017
Source: PwC Health Research Institute analysis, Kaiser Family Foundation, Kaiser Health News and Health Affairs
2008
Mental Health Parity Act amended
to require full parity. Insurance
companies must treat mental
health conditions on an equal
basis with physical conditions
when health policies cover both
2010
The Patient Protection and Affordable
Care Act was signed which required all
health insurance plans to include
coverage for the treatment of mental
health and substance use disorders
March 2016
President Obama announces a new task
force on mental health parity—aimed at
ensuring that people with mental illnesses
and substance abuse problems don’t face
discrimination in the health care system
Timeline of mental health parity legislation
March 2016
CMS finalizes mental health and
substance use disorder parity rule
for Medicaid and Children’s
Health Insurance Program
October 31, 2016
The interagency task force will be
responsible for delivering a report
to the President
2005 2010 2015 Mar. 2016 June 2016 Sept. 2016 Dec. 2016

8. © 2016 PwC. All rights reserved. PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity. Please seewww.pwc.com/structure
for further details. 172489-2016
Interest in high performance networks has
increased substantially
Source: PwC Health Research Institute analysis of PwC’s Health and Well-being Touchstone survey for 2014, 2015 and 2016
Percent of employers
Already implemented
a performance based
network
3%
6%
9%
34%
37%
43%
Considering the
implementation of a
performance based
network
‘14
‘15
‘16
‘14
‘15
‘16

9. © 2016 PwC. All rights reserved. PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity. Please seewww.pwc.com/structure
for further details. 172489-2016
The approval of a second specialty medication within a treatment
class can give PBMs leverage to extract sizable rebates
Discount = 40%
Discount = 5%
PBMs act to limit
formularies
to one treatment,
lowering the net
cost of drug Z
Specialty drug Z, a
first-in-class
breakthrough therapy,
has a list price of
$60,000 for a course
of treatment
Source: PwC Health Research Institute
$57,000
$36,000
Specialty drug M,
a direct competitor,
gains FDA approval

10. © 2016 PwC. All rights reserved. PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity. Please seewww.pwc.com/structure
for further details. 172489-2016
Source: PwC Health Research Institute estimate based on National Health and Nutrition Examination Survey and 2012 Truven Health Analytics claims data from employers
The impact of Hepatitis C therapy on medical cost trend declines
after 2016 as the number of patients treated declines
-0.4%
-0.2%
0%
0.2%
0.4%
0.6%
0.8%
1.0%
1.2%
20212020201920182017201620152014
ChangeinemployermedicalcosttrendduetoHepCdrugtherapy
Numberofpatientstreated
0
20,000
40,000
60,000
80,000
100,000
120,000
140,000
0.10%
0.15%
-0.23%
-0.10%
-0.08% -0.06% -0.04%
Annual change in medical cost trend
Annual number of
patients treated
Change in Medical Costs
Impact of Hepatitis C therapy on employer medical costs
0.71%

11. © 2016 PwC. All rights reserved. PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity. Please seewww.pwc.com/structure
for further details. 172489-2016
0%
1%
2%
3%
4%
5%
6%
7%
8%
High Cost, Low VolumeLow Cost, High VolumeHigh Cost, High Volume
The impact of a new specialty drug entering the market can vary
greatly depending on price and volume of sales
Source: PwC Health Research Institute estimate
Base medical cost trend Increase from new therapy use
6.5% 6.5% 6.5%
0.7%
0.0% 0.2%
Annual%changeinthemedicalcosttrend